Equities research analysts expect that Urogen Pharma Ltd (NASDAQ:URGN) will announce ($1.57) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Urogen Pharma’s earnings, with estimates ranging from ($1.86) to ($1.20). Urogen Pharma reported earnings per share of ($1.46) during the same quarter last year, which suggests a negative year over year growth rate of 7.5%. The company is scheduled to report its next earnings results on Thursday, February 27th.
According to Zacks, analysts expect that Urogen Pharma will report full year earnings of ($4.79) per share for the current year, with EPS estimates ranging from ($5.13) to ($4.45). For the next year, analysts expect that the firm will post earnings of ($4.68) per share, with EPS estimates ranging from ($5.41) to ($3.37). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Urogen Pharma.
Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Tuesday, November 12th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.26) by $0.20.
URGN has been the subject of a number of recent research reports. Stifel Nicolaus set a $41.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Sunday, October 20th. Oppenheimer lowered their price target on shares of Urogen Pharma from $70.00 to $62.00 in a research report on Wednesday. HC Wainwright set a $75.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Monday, October 21st. ValuEngine raised shares of Urogen Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Cowen reissued a “buy” rating on shares of Urogen Pharma in a research report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Urogen Pharma presently has a consensus rating of “Buy” and an average price target of $51.86.
In other Urogen Pharma news, CFO Peter P. Pfreundschuh sold 1,416 shares of Urogen Pharma stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $33.07, for a total value of $46,827.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is currently owned by insiders.
A number of institutional investors have recently modified their holdings of URGN. Tower Research Capital LLC TRC grew its stake in shares of Urogen Pharma by 1,500.0% in the third quarter. Tower Research Capital LLC TRC now owns 2,000 shares of the company’s stock worth $47,000 after acquiring an additional 1,875 shares during the period. SG Americas Securities LLC purchased a new position in Urogen Pharma during the third quarter valued at approximately $1,186,000. Parallel Advisors LLC purchased a new position in Urogen Pharma during the third quarter valued at approximately $36,000. Bank Hapoalim BM lifted its holdings in Urogen Pharma by 4.9% during the third quarter. Bank Hapoalim BM now owns 27,230 shares of the company’s stock valued at $653,000 after purchasing an additional 1,260 shares in the last quarter. Finally, California Public Employees Retirement System lifted its holdings in Urogen Pharma by 28.5% during the third quarter. California Public Employees Retirement System now owns 19,400 shares of the company’s stock valued at $462,000 after purchasing an additional 4,300 shares in the last quarter. 70.33% of the stock is owned by institutional investors and hedge funds.
Shares of URGN stock traded up $0.27 on Friday, hitting $26.57. 104,200 shares of the company’s stock traded hands, compared to its average volume of 165,714. Urogen Pharma has a one year low of $20.72 and a one year high of $55.49. The stock has a market capitalization of $549.59 million, a price-to-earnings ratio of -5.54 and a beta of 1.12. The company’s fifty day simple moving average is $22.96 and its 200 day simple moving average is $31.61.
Urogen Pharma Company Profile
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Recommended Story: What are the benefits of investing in REITs?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.